Back to Search Start Over

ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2

Authors :
Luo, Maowu
Bao, Lei
Xue, Yuanyuan
Zhu, Ming
Kumar, Ashwani
Xing, Chao
Wang, Jennifer E.
Wang, Yingfei
Luo, Weibo
Source :
Journal of Clinical Investigation. March 15, 2024, Vol. 134 Issue 6
Publication Year :
2024

Abstract

Breast cancer stem cells (BCSCs) mitigate oxidative stress to maintain their viability and plasticity. However, the regulatory mechanism of oxidative stress in BCSCs remains unclear. We recently found that the histone reader ZMYND8 was upregulated in BCSCs. Here, we showed that ZMYND8 reduced ROS and iron to inhibit ferroptosis in aldehyde dehydrogenase-high ([ALDH.sup.hi]) BCSCs, leading to BCSC expansion and tumor initiation in mice. The underlying mechanism involved a two-fold posttranslational regulation of nuclear factor erythroid 2-related factor 2 (NRF2). ZMYND8 increased stability of NRF2 protein through KEAP1 silencing. On the other hand, ZMYND8 interacted with and recruited NRF2 to the promoters of antioxidant genes to enhance gene transcription in mammospheres. NRF2 phenocopied ZMYND8 to enhance BCSC stemness and tumor initiation by inhibiting ROS and ferroptosis. Loss of NRF2 counteracted ZMYND8's effects on antioxidant genes and ROS in mammospheres. Interestingly, ZMYND8 expression was directly controlled by NRF2 in mammospheres. Collectively, these findings uncover a positive feedback loop that amplifies the antioxidant defense mechanism sustaining BCSC survival and stemness.<br />Introduction Breast cancer stem cells (BCSCs) are defined as a subpopulation of tumor cells with capability of self renewal and long-term maintenance of breast tumors and are responsible for breast [...]

Details

Language :
English
ISSN :
00219738
Volume :
134
Issue :
6
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.790361057
Full Text :
https://doi.org/10.1172/JCn71166.